Arthropod-borne viruses (arboviruses) are transmitted to humans primarily through the bites of infected mosquitoes and ticks. West Nile virus (WNV) is the leading cause of domestically acquired arboviral disease in the United States (1) . However, several other arboviruses also cause sporadic cases and seasonal outbreaks. This report summarizes surveillance data reported to CDC in 2014 for WNV and other nationally notifiable arboviruses, excluding dengue. Forty-two states and the District of Columbia (DC) reported 2,205 cases of WNV disease. Of these, 1,347 (61%) were classified as WNV neuroinvasive disease (e.g., meningitis, encephalitis, or acute flaccid paralysis), for a national incidence of 0.42 cases per 100,000 population. After WNV, the next most commonly reported cause of arboviral disease was La Crosse virus (80 cases), followed by Jamestown Canyon virus (11) , St. Louis encephalitis virus (10) , Powassan virus (8) , and Eastern equine encephalitis virus (8) . WNV and other arboviruses cause serious illness in substantial numbers of persons each year. Maintaining surveillance programs is important to help direct prevention activities.
In the United States, most arboviruses are maintained in transmission cycles between arthropods and vertebrate hosts (typically birds or small mammals). Humans usually become infected when bitten by infected mosquitoes or ticks. Personto-person transmission also occurs rarely through blood transfusion and organ transplantation. The majority of human arboviral infections are asymptomatic. Symptomatic infections most often manifest as a systemic febrile illness and, less commonly, as neuroinvasive disease. Most endemic arboviral diseases are nationally notifiable and are reported to CDC through ArboNET, a national arboviral surveillance system managed by CDC and state health departments (2, 3) . Using standard definitions, human cases with laboratory evidence of recent arboviral infection are classified as neuroinvasive disease or nonneuroinvasive disease (2) . Cases reported as encephalitis, meningitis, or acute flaccid paralysis are collectively referred to as neuroinvasive disease; others are considered nonneuroinvasive disease. Acute flaccid paralysis can occur with or without encephalitis or meningitis. In this report, any case reported as acute flaccid paralysis (with or without another clinical syndrome) was classified as acute flaccid paralysis and not included in the other categories. Because of the substantial associated morbidity, detection and reporting of neuroinvasive disease cases is assumed to be more consistent and complete than that of nonneuroinvasive disease cases. Therefore, incidence rates were calculated for neuroinvasive disease cases using U.S. Census 2014 mid-year population estimates.
In 2014, CDC received reports of 2,327 cases of nationally notifiable arboviral disease, among which 1,453 (62%) were classified as neuroinvasive disease. Cases were caused by WNV (2,205 cases, 95%), La Crosse virus (80), Jamestown Canyon virus (11) , St. Louis encephalitis virus (10) , Powassan virus (8) , Eastern equine encephalitis virus (8) , and unspecified California serogroup virus (5) . Cases were reported from 568 (18%) of the 3,141 U.S. counties; no cases were reported from Alaska, Delaware, Rhode Island, or Vermont.
A total of 2,205 WNV disease cases, including 1,347 (61%) neuroinvasive cases, were reported from 503 counties in 42 states and the District of Columbia. WNV disease cases peaked in late August; 90% of cases had illness onset during July-September ( Table 1 ). The median age of patients was 57 years (interquartile range [IQR] = 44-67 years); 1,403 (64%) were male. Overall, 1,589 (72%) patients were hospitalized, and 97 (4%) died. The median age of patients who died was 75 years (IQR = 65-83 years).
Of the 1,347 WNV neuroinvasive disease cases, 620 (46%) were reported as encephalitis, 565 (42%) as meningitis, 132 (10%) as acute flaccid paralysis, and 30 (2%) as other neurologic presentation. Among the 132 patients reported to have acute flaccid paralysis, 102 (77%) also had encephalitis or meningitis. Among all patients with WNV neuroinvasive disease, 1,294 (96%) were hospitalized, and 87 (6%) died.
The national incidence of WNV neuroinvasive disease was 0.42 per 100,000 population (Table 2 ). States with the highest incidence rates included Nebraska (2.2 per 100,000), North Dakota (1.6), California (1.4), South Dakota (1.4), Louisiana (1.3) and Arizona (1.2) (Table 2) (Figure) . Three states reported two thirds (66%) of the neuroinvasive disease cases: California (561 cases), Texas (253), and Arizona (80). WNV neuroinvasive disease incidence increased with increasing age, ranging from 0.03 per 100,000 among persons aged <10 years to 1.15 per 100,000 among those aged ≥70 years, and was higher among males (0.57 per 100,000) than among females (0.29).
Eighty La Crosse virus disease cases were reported from nine states; 76 (95%) were neuroinvasive ( Table 1 ). Dates of illness onset for La Crosse virus disease cases ranged from March to October; 73 (91%) had onset during July-September. Fortytwo (53%) patients were female. The median age of patients was 8 years (IQR = 6-11 years); 72 (90%) were aged <18 years. A total of 79 (99%) patients were hospitalized; three (4%) died. La Crosse virus neuroinvasive disease incidence was highest in Ohio (0.26 per 100,000), North Carolina (0.23), and Tennessee (0.17) ( Table 2) .
Eleven Jamestown Canyon virus disease cases were reported from four states (Massachusetts, Minnesota, Tennessee, and Wisconsin); six were neuroinvasive (Table 1) . Tennessee reported its first Jamestown Canyon virus disease cases in 2014. Dates of illness onset ranged from May to September, with eight occurring during July-September. The age distribution of patients was bimodal, with four patients aged <18 years and six aged >60 years. Six patients were female. Seven patients were hospitalized; none died. In addition to the La Crosse virus and Jamestown Canyon virus cases, five other cases of California serogroup virus disease were reported for which the specific infecting virus was unknown.
Ten St. Louis encephalitis virus disease cases were reported from five states (Alabama, Arizona, Florida, Mississippi, and Texas); six were neuroinvasive ( Table 1) . Dates of illness onset ranged from January-October; six had onset during July-September. The median age of patients was 55 years (IQR: 47-60 years); six were female. All patients were hospitalized; none died.
Eight Powassan virus disease cases were reported from four states (Massachusetts, New Jersey, New York, and Wisconsin); seven were neuroinvasive (Table 1) . Three patients (38%) had onset in May, and 5 (62%) had onset during July-September. The median age of patients was 65 years (IQR = 51-70 years); six were male. All patients were hospitalized; none died.
Eight Eastern equine encephalitis virus neuroinvasive disease cases were reported from five states (Alabama, Maine, Michigan, New Hampshire, and New York (Table 1 ). All eight patients had illness onset during July-September. The median age of patients was 60 years (IQR = 52-69 years); four were male. All eight patients were hospitalized; two died.
Discussion
In 2014, WNV was the most common cause of neuroinvasive arboviral disease in the United States, accounting for 93% of all neuroinvasive cases. Nationally, WNV neuroinvasive disease incidence was similar to the median incidence during 2002-2013 (median = 0.40; range = 0.13-1.02) (3, 4) . However, California reported a record 561 neuroinvasive disease cases, 83% more than the next highest year (2005) . Within California, 70% of all neuroinvasive disease cases were reported from just two counties (Los Angeles and Orange). These findings highlight the focal nature of WNV outbreaks.
As has been reported in previous years, La Crosse virus was the most common cause of neuroinvasive arboviral disease among children (1); it is not known why the incidence of La Crosse virus disease is highest among children (5) . Jamestown Canyon virus disease cases continue to be reported from new locations (e.g., Tennessee) following the implementation of routine Jamestown Canyon virus antibody testing at CDC in 2013 (6) . Eastern equine encephalitis virus disease, although rare, remained the most severe domestic arboviral disease, with two deaths among eight patients. Over 90% of arboviral disease cases occurred during April-September, emphasizing 
the importance of focusing public health interventions during this period. The findings in this report are subject to at least three limitations. First, ArboNET is a passive surveillance system that relies on clinicians to consider the diagnosis of an arboviral disease and obtain appropriate diagnostic tests, and on health care providers and laboratories to report laboratory-confirmed cases to public health authorities. Second, testing and reporting are incomplete, leading to a substantial underestimate of the actual number of cases (7) . For example, data from previous studies suggest there are an estimated 30-70 nonneuroinvasive disease cases for every reported case of WNV neuroinvasive disease (8) (9) (10) . Extrapolating from the 1,347 WNV neuroinvasive disease cases reported, an estimated 40,000-94,000 nonneuroinvasive disease cases might have occurred in 2014. However, only 858 (1%-2%) were diagnosed and reported.
Finally, this report underestimates the overall disease burden for arboviral diseases in the United States during 2014, because it does not include dengue or arboviral diseases that were not nationally notifiable such as Colorado tick fever and chikungunya. Chikungunya became a nationally notifiable condition in 2015.
Arboviruses continue to cause substantial morbidity in the United States, although reported numbers of cases vary annually. Cases occur sporadically, and the epidemiology varies by virus and geographic area. The weather, zoonotic host and vector abundance, and human behavior are all factors that can influence when and where outbreaks occur. Because of this complex ecology, it is difficult to predict how many cases of disease might occur in the future and in what areas; therefore, surveillance is essential to identify outbreaks and guide prevention efforts. Health care providers should consider arboviral Nebraska  41  2.18  ----------North Dakota  12  1.62  ----------South Dakota  12  1.41  ----------S Atlantic  38  0.06  28  0.04  ------2  <0.01  Delaware  ------------District of Columbia  1  0.15  ----------Florida  12  0.06  1  0.01  ------2  0.01  Georgia  11  0.11  1  0.01  --------Maryland  6  0.10  ----------North Carolina  --23  0.23  --------South Carolina  3  0.06  ----------Virginia  5  0.06  2  0.02  --------West Virginia  --1  0.05  --------See table footnotes on next page. infections in the differential diagnosis of cases of aseptic meningitis and encephalitis, obtain appropriate specimens for laboratory testing, and promptly report cases to public health authorities (2) . Because human vaccines against domestic arboviruses are not available, prevention depends on community and household efforts to reduce vector populations (e.g., applying insecticides and reducing breeding sites), personal protective measures to decrease exposure to mosquitoes and ticks (e.g., use of repellents and wearing protective clothing), and screening of blood donors. Athletes are not a typical at-risk group for smoking combustible tobacco products, because they are generally health conscious and desire to remain fit and optimize athletic performance (1). In contrast, smokeless tobacco use historically has been associated with certain sports, such as baseball (2) . Athletes might be more likely to use certain tobacco products, such as smokeless tobacco, if they perceive them to be harmless (3); however, smokeless tobacco use is not safe and is associated with increased risk for pancreatic, esophageal, and oral cancers (4) . Tobacco use among youth athletes is of particular concern, because most adult tobacco users first try tobacco before age 18 years (5 The national Youth Risk Behavior Survey is a biennial, school-based survey of U.S. high school students.* For each survey, a three-stage cluster sample design was used to produce a nationally representative sample of students in grades 9-12 who attend public and private schools. Students completed the self-administered questionnaire during one class period and recorded their responses directly on a computer scannable booklet or answer sheet. During 2001-2013, sample sizes ranged from 13,583 to 16,410; overall response rates ranged from 63% to 71%.
Current use of combustible tobacco products, smokeless tobacco products, and any tobacco product was self-reported. † Athletic status was assessed with the question, "During the past 12 months, on how many sports teams did you play? (Count any teams run by your school or community groups.)" Response options were "0 teams," "1 team," "2 teams," or "3 or more teams." Students who selected a response other than "0 teams" were categorized as athletes; all other responses were categorized as nonathletes.
Data were weighted to yield nationally representative estimates. Prevalence estimates were computed overall and by grade (9th, 10th, 11th, or 12th), sex (male or female), race/ethnicity (non-Hispanic white, non-Hispanic black, or Hispanic), § and athletic status (athlete or nonathlete). Estimates were also computed on the basis of the number of sports teams on which students participated (0, 1, 2, ≥3 Categorical response options to all three questions were "0 days," "1 or 2 days," "3 to 5 days," "6 to 9 days," "10 to 19 days," "20 to 29 days," or "all 30 days." Students who provided a response other than "0 days" were categorized as current users of each respective product. § Data are presented only for non-Hispanic white, non-Hispanic black, and Hispanic students because sample sizes for other race/ethnic groups were too small to provide statistically reliable estimates. current use of combustible tobacco occurred among all subgroups (sex, grade, race/ethnicity, and athletic status). Significant increases in current smokeless tobacco use were observed among 12th grade students and athletes overall. Among athletes, significant increases in current smokeless tobacco use were observed among both sexes, 11th-and 12th-grade students, and Hispanic students; among nonathletes, a significant increase was observed among Hispanic students only (p<0.05 for linear trends). During 2013, the adjusted odds of current use of any tobacco, combustible tobacco, and smokeless tobacco were significantly higher among male students than female students, overall, and among athletes (p<0.05). Among nonathletes, the odds of current use of any tobacco and smokeless tobacco were significantly higher among male students, whereas no sex difference was observed for combustible tobacco use. Students in 9th and 10th grades had significantly lower odds of current use of any tobacco and combustible tobacco than 12th grade students, overall as well as among athletes and nonathletes; however, with the exception of 9th grade athletes, no significant grade differences existed for current use of smokeless tobacco. Students in 11th grade did not differ significantly in current use of any tobacco, combustible tobacco, or smokeless tobacco compared with 12th grade students, overall or among athletes or nonathletes. Overall and among both athletes and nonathletes, nonHispanic black and Hispanic students had significantly lower odds of current use of any tobacco, combustible tobacco, and smokeless tobacco compared with non-Hispanic white students, with one exception: Hispanic athletes did not differ significantly from non-Hispanic white athletes in current use of combustible tobacco.
Athletes had significantly lower adjusted odds of current combustible tobacco use than nonathletes during 2001-2013; conversely, athletes had significantly higher adjusted odds of current smokeless tobacco use than nonathletes in 2001, 2005, 2011, and 2013 (p<0.05) ( Figure 1 ). An inverse association between level of sports team participation and the prevalence of combustible tobacco use was identified; during 2013, prevalence of combustible tobacco use was 21.3%, 19.6%, 17.1%, and 15.8% among students participating in zero, one, two, or three or more sports teams, respectively (p<0.05) ( Figure 2 ). In contrast, a positive association between the level of sports team participation and the prevalence of smokeless tobacco use was identified; during 2013, prevalence of smokeless tobacco use was 5.9%, 10.2%, 11.5%, and 12.5% among students participating in zero, one, two, or three or more sports teams, respectively (p<0.05).
During 2001-2013, current use of smokeless tobacco increased significantly among high school athletes, but not among high school nonathletes; athletes reported higher use of smokeless tobacco, but lower use of combustible tobacco products than nonathletes. The lower use of combustible tobacco products among athletes might reflect an awareness of the adverse consequences of smoking on athletic performance, including reduced lung and cardiovascular function, reduced overall fitness, and poor wound healing (6) . However, the higher smokeless tobacco use among athletes compared with nonathletes suggests athletes might perceive these products as being harmless, socially acceptable, or even a way to enhance athletic performance (3, 7) . Using smokeless tobacco products can adversely affect athletic performance and cause disease and premature death because they can contain nicotine, toxins, and carcinogens (4, 6) . For example, several professional U.S. athletes with a history of smokeless tobacco use have had a diagnosis of, or died from, oral cancer (8) . Given that use of tobacco by youth in any form is unsafe, efforts are warranted to educate youth about the dangers of use of all forms of tobacco products, irrespective of whether they are combustible, noncombustible, or electronic (6) . ¶ The tobacco industry has marketed smokeless tobacco products as an alternative to cigarettes in situations where smoking is prohibited (9) , which might further promote smokeless tobacco use among athletes. Although smokeless tobacco use is prohibited in minor league baseball, its use is restricted but not prohibited in major league baseball.** Smokeless tobacco use among professional athletes is an important issue because they often are considered role models by youth (5). On May 8, 2015, San Francisco, Adjusted odds ratios Year * Adjusted for grade, sex, and race/ethnicity in a binary logistic regression model. Adjusted odds ratios are for athletes, using nonathletes as the reference category. † Current combustible tobacco use was defined as having smoked cigarettes or cigars, cigarillos, or little cigars on ≥1 day during the 30 days before the survey. § Current smokeless tobacco use was defined as having used chewing tobacco, snuff, or dip on ≥1 day during the 30 days before the survey. ¶ Athletes were defined as students who played on at least one sports team, run by their school or community groups, during the 12 months before the survey. Nonathletes were students who did not play on a sports team during the 12 months before the survey.
California, became the first U.S. city to pass a law prohibiting the use of smokeless tobacco at all baseball venues and athletic fields, effective January 1, 2016. † † The city of Boston, Massachusetts has also proposed an ordinance prohibiting smokeless tobacco use at all professional and amateur sports venues in Boston. § § Implementing and enforcing tobacco-free policies that prohibit all tobacco use on school campuses and at all public recreational facilities, including stadiums, parks, and school gymnasiums, by players, coaches, referees, and fans might help reduce tobacco use among student athletes (5) . In addition to tobacco-free policies, continued implementation of other population level, evidence-based interventions outlined in the CDC Best Practices for Comprehensive Tobacco Control Programs ¶ ¶ is also critical to reducing all forms of tobacco use among youth; these interventions include increasing tobacco product prices, warning about the dangers of tobacco use, and increasing access to tobacco use cessation resources.
The differences in tobacco use among population subgroups (overall and among athletes), including the higher prevalence of both combustible tobacco and smokeless tobacco use among male students, non-Hispanic white students, and students in 11th and 12th grade, might be related to dissimilarities among these groups in socialization with tobacco-using peers, exposure and receptivity to pro-tobacco advertising, and targeted marketing of tobacco products by the tobacco industry (5) .
The findings in this report are subject to at least six limitations. First, sports team participation and tobacco use were self-reported and might be subject to misreporting of tobacco use, which could lead to under-or overestimating tobacco use, as well as misclassification of athlete status (e.g., respondents who engaged fitness activities, but did not play on a school or community team would (10); thus, the extent of any bias from this exclusion is likely minimal.
Sports activities present opportunities to reach young persons with public health interventions.*** Tobacco education programs tailored to high school athletes, coupled with other population-level evidence-based interventions, have the potential to increase awareness of the dangers of tobacco use and to reduce the use of all forms of tobacco, including smokeless tobacco, among youth.
Summary
What is already known on this topic?
Athletes might be more likely to use certain tobacco products, such as smokeless tobacco, if they perceive them to be harmless; however, smokeless tobacco use is not safe, and is associated with increased risk for oral, esophageal, and pancreatic cancers.
What is added by this report?
Data from national Youth Risk Behavior Surveys indicate that current (≥1 day during the past 30 days) use of any tobacco product by U.S. high school students declined from 33.9% in 2001 to 22.4% in 2013; however, current smokeless tobacco use increased from 10.0% to 11.1% among high school athletes. Compared with nonathletes, athletes had higher odds of being current smokeless tobacco users, but lower odds of being current combustible tobacco users.
What are the implications for public health?
Tobacco education programs tailored to high school athletes, coupled with other population-level, evidence-based interventions, have the potential to increase awareness of the harmfulness of all tobacco products and reduce all forms of tobacco use, including smokeless tobacco, among youth. *** Additional information available at http://www.cdc.gov/tobacco/youth/ sports.
Enteroviruses (EVs) and human parechoviruses (HPeVs) are small, non-enveloped RNA viruses in the Picornaviridae family, which are known or suspected to cause a spectrum of clinical manifestations in humans. Although most infected persons are asymptomatic, mild presentations can include respiratory infections, herpangina, and hand, foot, and mouth disease. Among the more severe syndromes associated with EV and HPeV infection are acute flaccid paralysis, meningitis, encephalitis, myocarditis, and sepsis. Neonates and infants are at higher risk for infection and for severe clinical outcomes than older children or adults (1-3). As of August 2015, a total of 16 HPeV types and 118 EV types (within four EV species known to infect humans: A, B, C, and D) had been identified, and the spectrum of illness caused differed among virus types (4). To describe trends in EV and HPeV circulating in the United States during 2009-2013, CDC summarized detections reported through two surveillance systems. The most commonly reported types of EV and HPeV during this period were coxsackievirus (CV) A6 and HPeV3. The large number of CVA6 detections likely reflected an increase in testing in response to an outbreak of severe hand, foot, and mouth disease in late 2011 and 2012 (5). Most HPeV3 detections originated from a single hospital that routinely tested for HPeV (6) . Clinicians and public health practitioners should consider the EV and HPeV types recently circulating in the United States to inform diagnostic and surveillance activities. When EV and HPeV typing is performed, clinical and public health laboratories should routinely report their results to improve the reliability and generalizability of surveillance data.
The National Enterovirus Surveillance System (NESS) is a passive surveillance system that has been collecting laboratory data on types of EV and HPeV in the United States since the 1960s. Participating laboratories are asked to report detections monthly to NESS, as well as demographic (age, sex, and state) and laboratory (specimen collection date, specimen type, virus type) data. During 2009-2013, 17 laboratories from across the United States reported data to NESS, including the CDC Polio and Picornavirus Laboratory, the departments of health of 13 states and one city, one private reference laboratory, and one hospital laboratory. Detections were reported in 45 states and Puerto Rico (Figure 1) . The U.S. Census Region most often named as the patients' location was the Midwest (40.0% of the 2,271 patients for whom state or territory was known), followed by the South (29.1%).
During 2009-2013, 2,724 specimens representing 2,532 patients tested for EV and HPeV were reported to NESS; the number of specimens submitted each year ranged from 392 in 2011 to 870 in 2012. The most commonly reported specimen types among those for which type was known (77.5% of 2,724 specimens) were cerebrospinal fluid (31.6%) and throat/ nasopharyngeal swab (29.8%). Other frequently reported specimen types included stool/rectal swab (13.5%), tissue culture isolates (7.5%), and lesion swab/scraping (3.6%). Of the 1,763 patients for whom sex was reported, 56.2% were male. Age was reported for 1,763 patients. The age groups most widely represented were children aged <1 year (687 [39.0%]) and children aged 1-4 years (387 [22.0%] (Figure 2 ).
Discussion
The findings in this report are consistent with previous observations of changes over time in the virus types that predominate. Some types appear to circulate every year, whereas others circulate in a cyclical fashion with epidemic years followed by years with decreased activity (8). Type-based enterovirus surveillance in the United States has five objectives: 1) to help public health practitioners determine long-term patterns of circulation for individual EVs; 2) to help interpret trends in enteroviral diseases (e.g., aseptic meningitis) by associating them with circulating types; 3) to assist with recognition of outbreaks associated with circulating types; 4) to help guide development of new diagnostic tests and therapies; and 5) to monitor poliovirus detections, thereby supplementing clinician-based poliomyelitis testing in the United States. Both paralytic poliomyelitis and nonparalytic poliovirus infections are nationally notifiable.
Frequency of reports to NESS is greatly influenced by increased awareness and demand for testing during outbreak periods. As a result, reports to NESS might be a closer reflection of outbreak-driven testing than of endemic circulation of the broader range of enteroviruses. During 2009-2013, the most common EV type reported to NESS was CVA6, of which an outbreak was first reported in the United States in 2010 and which was the predominant circulating type reported in 2012. Outbreaks of hand, foot, and mouth disease associated with CVA6 have been reported internationally since 2008 (9,10), including cases that occurred in multiple U.S. states during 2011-2012 (5). Other frequent reports to NESS include HPeV3, an important cause of neonatal sepsis.
The findings in this report are subject to at least five limitations. First, EV and HPeV infections other than poliovirus infections are not nationally notifiable in the United States. NESS is a passive system that relies on voluntary participation from laboratories, so findings are not necessarily representative of national or regional enterovirus activity. Second, the findings are limited by the lack of clinical information. Third, most typing is performed during the summer months; circulation during other parts of the year might be underrecognized.
Fourth, although monthly NESS reporting is encouraged, not all participating laboratories submit timely data, which can delay the compilation of accurate data. Finally, the number of laboratories that continue to test for specific EV types has decreased over time as testing requests from clinicians become less frequent and as viral culture methods are discontinued. Only a handful of U.S. laboratories have the capacity to test for HPeV. Although molecular detection methods are gradually coming into wider use, some clinical laboratories use them only to determine the presence of EV and do not further test for type. HPeV are not detected by EV molecular methods. EV and HPeV molecular typing methods are carried out in a small number of state laboratories, but mostly remain the purview of large, specialized reference laboratories.
NESS allows monitoring of temporal patterns of EV and HPeV circulation based on voluntary laboratory reporting of isolates by type. NREVSS demonstrates EV activity over a wider geographic area and has more laboratory participation but does not provide information on type, demographic characteristics, or HPeV detections. The combined systems provide the best available data on EV circulation in the United States.
Understanding of currently circulating EV and HPeV types relies on voluntary reports to NESS from public health and clinical laboratories. The long-term viability of NESS depends on 1) maintaining and modernizing the capacity to identify and type EVs and HPeVs among public health and clinical laboratories, 2) continued regular reporting by currently participating laboratories, and 3) increasing the number of participating laboratories. 
Summary
What is already known on this topic? Enteroviruses (EVs) and human parechoviruses (HPeVs) can cause a wide spectrum of clinical illness, ranging from asymptomatic infections to severe illnesses and death. A total of 134 EV and HPeV types have been identified to date, and they cause different but overlapping clinical illnesses, including aseptic meningitis, hand, foot, and mouth disease, and acute flaccid paralysis. Because EV and HPeV infections are not nationally notifiable, with the exception of poliovirus, surveillance for these infections in the United States is passive and voluntary.
What is added by this report?
Based on data from the National Enterovirus Surveillance System, the most commonly reported types of EV and HPeV during 2009-2013 were coxsackievirus A6 (CVA6) and human parechovirus 3 (HPeV3), each of which accounted for 12.3% of reports with known virus type (N = 1,819). The large number of CVA6 detections likely reflect an increase in testing in response to an outbreak of severe hand, foot, and mouth disease in late 2011 and 2012. Most HPeV3 detections originated from a single hospital that routinely tested for HPeVs.
What are the implications for public health practice? EV and HPeV surveillance data might be used to determine patterns of circulation for individual virus types, interpret trends in enteroviral disease, assist with the recognition of outbreaks, and guide development of new diagnostic tests and therapies. 
]). The Advisory Committee on Immunization
Practices (ACIP) currently recommends that a dose of PCV13 be followed by a dose of PPSV23 in all adults aged ≥65 years who have not previously received pneumococcal vaccine and in persons aged ≥2 years who are at high risk for pneumococcal disease because of underlying medical conditions (Table) (1-4). The recommended intervals between PCV13 and PPSV23 given in series differ by age and risk group and the order in which the two vaccines are given (1-4) .
On June 25, 2015, ACIP changed the recommended interval between PCV13 followed by PPSV23 (PCV13-PPSV23 sequence) from 6-12 months to ≥1 year for immunocompetent adults aged ≥65 years. Recommended intervals for all other age and risk groups remain unchanged. This report outlines the rationale for this change and summarizes the evidence considered by ACIP to make this recommendation.
In August 2014, ACIP recommended routine use of a dose of PCV13 followed by a dose of PPSV23 6-12 months later among immunocompetent adults aged ≥65 years (1). Adults aged ≥65 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants are recommended to receive PCV13 first, followed by PPSV23 ≥8 weeks later (2) . ACIP also recommended that all adults aged ≥65 years who already received PPSV23 should receive a dose of PCV13 ≥1 year after receipt of PPSV23 (PPSV23-PCV13 sequence). The difference in the recommended interval depending on the order in which the two vaccines were given added significant complexity to the recommendation and created implementation challenges for this age group. To simplify the recommendations, ACIP reviewed existing data to evaluate potential areas for harmonization of recommended dosing intervals. Specifically, ACIP assessed whether available evidence would support changing the recommended interval for the PCV13-PPSV23 sequence for immunocompetent adults aged ≥65 years from 6-12 months to ≥1 year and thus be harmonized with the recommended interval for the PPSV23-PCV13 sequence in the same age group.
No clinical studies evaluating efficacy of the two vaccines given in series are available. Therefore, current recommendations are based on best available evidence from immunogenicity studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was used by ACIP to formulate the existing recommendations for immunocompromised children (http://www.cdc.gov/vaccines/ acip/recs/grade/pneumo-immuno-child.html), immunocompromised adults (http://www.cdc.gov/vaccines/acip/recs/grade/ pneumo-immuno-adults.html), and adults ≥65 years (http:// www.cdc.gov/vaccines/acip/recs/grade/pneumo-vac-adult. html) (1) (2) (3) . No new evidence was available to inform harmonization of intervals; therefore, the GRADE process was not repeated. In addition, the immunogenicity studies were not designed to evaluate the optimal interval between the two vaccines. When both PCV13 and PPSV23 are to be administered, PCV13 is recommended before PPSV23, based on studies demonstrating a better response to serotypes common to both vaccines when PCV was given first (5-7).
Studies evaluating the immune response to a conjugate vaccine (PCV7 or PCV13) followed by the polysaccharide vaccine (PCV-PPSV23 sequence) at intervals of 2, 6, 
Recommendations for routine use of vaccines in children, adolescents and adults are developed by the Advisory Committee on Immunization Practices (ACIP). ACIP is chartered as a federal advisory committee to provide expert external advice and guidance to the Director of the Centers for Disease Control and Prevention (CDC) on use of vaccines and related agents for the control of vaccine-preventable diseases in the civilian population of the United States. Recommendations for routine use of vaccines in children and adolescents are harmonized to the greatest extent possible with recommendations made by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetricians and Gynecologists (ACOG). Recommendations for routine use of vaccines in adults are harmonized with recommendations of AAFP, ACOG, and the American College of Physicians (ACP). ACIP recommendations approved by the CDC Director become agency guidelines on the date published in the Morbidity and Mortality Weekly Report (MMWR). Additional information about ACIP is available at http://www.cdc.gov/vaccines/acip.
antibody levels against serotypes common to both vaccines were higher than the pre-PCV baseline (5, 6, (8) (9) (10) (11) (12) (13) . Eight studies compared immune responses among immunocompetent adults aged ≥50 years after a PCV-PPSV23 sequence with responses following PCV or PPSV23 administered alone (5, 6, (8) (9) (10) (11) (12) (13) . Four studies showed that antibody responses (measured by opsonophagocytic activity [OPA] or immunoglobulin G [IgG] levels or both) following PCV7-PPSV23 doses given 6 months apart were better than or equivalent to responses following PCV7 or PPSV23 alone for most pneumococcal serotypes measured (6, 8, 11, 12) . Another study showed that a 1-year interval between receipt of conjugate vaccine and polysaccharide vaccine (PCV7-PPSV23 sequence) also led to improved immune responses compared with those following a single PPSV23 dose (13) . Comparison of antibody responses after a PCV13-PPSV23 sequence to responses following PCV13 or PPSV23 alone, across two studies with intervals of 1 year and 3-4 years between the two vaccines, indicated that the responses to a larger number of serotypes are improved with a 3-4 year interval compared with a 1-year interval (5, 9) . One study among pneumococcal vaccine-naïve Alaska Native adults aged 55-70 years included direct comparison between intervals of 2 months and 6 months between receipt of PCV7 and PPSV23. No differences in the immune responses were observed; however, the group with a 2-month interval between doses reported more injection site swelling than the group with a 6-month interval (10). In summary, these studies of PCV-PPSV23 sequence among immunocompetent adults suggest that 1) shorter intervals (e.g., 8 weeks), may be associated with increased local reactogenicity when compared with longer intervals, and 2) longer intervals (e.g., ≥1 year) may lead to an improved immune response against serotypes in both vaccines compared with a single dose of PCV13 or PPSV23. Additionally, changing the recommended interval for the PCV13-PPSV23 sequence to ≥1 year would allow the recommended interval for immunocompetent adults aged ≥65 years to be the same, regardless of the order in which the two vaccines are given (Box).
ACIP considered additional factors when determining whether a change to the intervals is warranted. These factors include the risk window for protection against disease caused by serotypes unique to PPSV23, the timing for the next visit to the vaccination provider, as well as revised Centers for Medicare and Medicaid Services (CMS) regulations allowing for coverage of the two pneumococcal vaccines when given in series and administered 1 year apart. Approximately 40% of invasive pneumococcal disease among adults aged ≥65 years is caused by serotypes unique to PPSV23. The potential change in the interval for the PCV13-PPSV23 sequence is most likely to affect the youngest adults in this age group who are more likely to be pneumococcal vaccine naïve. The incidence of disease caused by serotypes unique to PPSV23 is lowest among these adults (14) . The 2012 National Health Interview Survey results suggest that >85% of adults in the United States aged ≥65 years had at least one encounter with a health professional within the preceding 6 months, and >93% within the preceding year (15) . Therefore, the 1-year interval would offer the best opportunity for the majority of eligible adults aged ≥65 years to receive the recommended pneumococcal vaccine series during their existing healthcare encounters and not require an extra visit.
The recently revised CMS regulations for pneumococcal vaccines allow for Medicare coverage of a different, second pneumococcal vaccine 1 year after the first vaccine is given (16) . The change in the ACIP recommended interval for the PCV13-PPSV23 sequence would make ACIP recommendations consistent with the current Medicare policy.
Recommended intervals between PCV13 and PPSV23 for persons aged ≥2 years with medical indications to receive both vaccines remain unchanged (Table) . PPSV23 is recommended to be given ≥8 weeks after PCV13 for children and adults aged ≥19 years with certain underlying medical conditions (including adults aged ≥65 years with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants). Studies among HIV-positive adults evaluating the immune response to PPSV23 administered 4 or 8 weeks after PCV7 showed statistically significant increases in antibody levels compared with response to PPSV23 alone (17, 18) . The currently recommended 8-week interval minimizes the risk window for invasive pneumococcal disease caused by serotypes unique to PPSV23 in these highly vulnerable groups.
ACIP Recommendations for Intervals Between PCV13 Followed by PPSV23 for Immunocompetent Adults Aged ≥65 Years
For immunocompetent adults aged ≥65 years who have not previously received pneumococcal vaccine, ACIP makes the following recommendation for intervals between PCV13 followed by PPSV23: A dose of PPSV23 should be given ≥1 year following a dose of PCV13. The two vaccines should not be co-administered. If a dose of PPSV23 is inadvertently given earlier than the recommended interval, the dose need not be repeated.
Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Events Reporting System (VAERS). Reports can be submitted to VAERS online, by facsimile, or by mail. More information about VAERS is available by calling 1-800-822-7967 (toll-free) or online at http://vaers.hhs.gov. Persons who previously received PPSV23 at age ≥65 years PPSV23 already received at age ≥65 years ≥1 year
PCV13
Pneumococcal vaccine-naïve persons aged ≥65 years PCV13 at age ≥65 years PPSV23
≥1 year
Abbreviations: PCV13 = 13-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine. Notes: For adults aged ≥65 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants, the recommended interval between PCV13 followed by PPSV23 is ≥8 weeks. For those for who previously received PPSV23 when aged <65 years and for whom an additional dose of PPSV23 is indicated when aged ≥65 years, this subsequent PPSV23 dose should be given ≥1 year after PCV13 and ≥5 years after the most recent dose of PPSV23. 
Summary
What is currently recommended?
The Advisory Committee on Immunization Practices (ACIP) currently recommends that both 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) be given to all immunocompetent adults aged ≥65 years. ACIP recommends that PCV13 be given first followed by PPSV23 6-12 months later. ACIP also recommends that adults aged ≥65 years who already received a dose of PPSV23, should also receive a dose of PCV13 ≥1 year after the dose of PPSV23. Among persons aged ≥2 years with medical indications to receive both PCV13 and PPSV23 in a series, including adults aged ≥65 years with immunocompromising conditions, functional or anatomic asplenia, cochlear implants, or cerebrospinal fluid leaks, a dose of PPSV23 should be given ≥8 weeks after a dose of PCV13.
Why are the recommendations being modified now?
To simplify the recommendations for PCV13 and PPSV23 use among immunocompetent adults aged ≥65 years, ACIP recommended harmonization of recommended intervals between PCV13 and PPSV23 regardless of the order in which the two vaccines are given.
What are the new recommendations?
ACIP recommends that both PCV13 and PPSV23 be given in series to adults aged ≥65 years. A dose of PCV13 should be given first followed by a dose of PPSV23 at least 1 year later to immunocompetent adults aged ≥65 years. The two vaccines should not be co-administered. If a dose of PPSV23 is inadvertently given earlier than the recommended interval, the dose need not be repeated.
On The individual antigens (diphtheria and tetanus toxoids; pertussis antigens [pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3]; and inactivated poliovirus types 1, 2, and 3) contained in a dose of Quadracel are identical to the antigens contained in Sanofi Pasteur's DTaP-IPV-Hib (Pentacel) vaccine (3, 5) . Quadracel contains no preservatives and is administered as an intramuscular injection, preferably into the deltoid muscle of the upper arm. One clinical trial conducted in U.S. children aged 4 through 6 years showed that Quadracel and separately administered DTaP (Daptacel) and IPV (Ipol, Sanofi Pasteur) vaccines had comparable safety and reactogenicity profiles, with or without a coadministered second dose of measles, mumps, and rubella (MMR) and varicella (VAR) vaccines (3) . The immunogenicity of all antigens was noninferior among the treatment groups, with or without a coadministered second dose of MMR and VAR vaccines.
Indications and Guidance for Use
Quadracel is indicated for use as the fifth dose of DTaP and fourth or fifth dose of IPV in children aged 4 through 6 years who received DTaP-IPV-Hib (Pentacel) and/or DTaP (Daptacel) vaccine as the first 4 doses (2,3) . This vaccine should not be administered to children aged <4 years or ≥7 years. If Quadracel vaccine is inadvertently administered before age 4 years for an earlier dose of the DTaP and/or IPV series and if minimum interval requirements have been met, the dose may be counted as valid for the DTaP and/or IPV series and does not need to be repeated (6) . Note that the final dose in the IPV series must be administered at age ≥4 years regardless of the number of previous doses, and with a minimum interval of 6 months from the previous dose (7) . Therefore, a dose of Quadracel vaccine administered before the fourth birthday cannot be counted as a valid final dose of IPV. Data are limited on the safety and immunogenicity of interchanging DTaP vaccines from different manufacturers (8) .
ACIP recommends that, whenever feasible, the same manufacturer's DTaP vaccines should be used for each dose in the series. However, vaccination should not be deferred because the type of DTaP vaccine previously administered is unavailable or unknown (6) .
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose
Jennifer Liang, DVM 1 ; Greg Wallace, MD 2 ; Gina Mootrey, DO 1
Introduction
Cardiovascular disease (CVD) is responsible for nearly 800,000 deaths and approximately $320 billion in costs in the United States each year (1) . Studies have identified a number of modifiable CVD risk factors, including high blood pressure, smoking, high blood cholesterol, diabetes, and being overweight or obese (1, 2) . Differences in prevalence of CVD risk factors play important roles in persistent racial, socioeconomic, and regional disparities in CVD morbidity and mortality in the United States (3, 4) .
To help with the prevention and management of CVD, several multivariable prediction models have been developed to predict the risk for developing CVD based on a person's cardiovascular risk factor profile (2, 5, 6) . Most of these models estimate a person's absolute risk for having a coronary heart disease event or stroke within a certain period (e.g., in the next 10 years). However, predicted absolute risk is an epidemiologic concept that might be difficult for members of the public to interpret and, therefore, its usefulness in motivating lifestyle changes or adherence to recommended therapeutic interventions might be limited (7, 8) . Moreover, its use might provide false assurance, especially among younger persons whose chronological age might conceal the effects that risk factors (e.g., smoking and uncontrolled hypertension) have on their long-term CVD risk (9) .
In 2008, the Framingham Heart Study introduced the concept of heart age (i.e., the predicted age of the vascular system of a person based on his or her cardiovascular risk factor profile) (10) . The comparison of heart age to chronological age represents an alternative way to express a person's risk for having a CVD event* and provides information about a person's cardiovascular health that is not clear from the 10-year risk score alone. This method might simplify risk communication and motivate more persons, especially younger persons, to establish heart-healthy lifestyle changes and adhere to recommended treatment strategies (7, 8, 11) . However, no study has provided population-level estimates of heart age and examined disparities in heart age among U.S. adults. This study provides national estimates for heart age, identifies differences between heart age and chronological age, and examines the racial, sociodemographic, and state-level disparities in heart age among U.S. adults aged 30-74 years using 2011 and 2013 Behavioral Risk Factor Surveillance System (BRFSS) data.
Methods
BRFSS is a state-based, random-digit-dialed telephone survey that uses a multistage sampling design to select a state-specific sample from noninstitutionalized U.S. civilian adults aged ≥18 years; a CVD-specific module is conducted in odd-numbered years. Detailed methodology on BRFSS is available at http://www.cdc.gov/brfss. Weighted 2011 and 2013 BRFSS data collected from all 50 states and the District of Columbia were combined to obtain stable estimates; the median combined response rate for each year was 49.7% and 45.9%, respectively. Among 981,660 participants, 403,135 (41%) were excluded, including 234,936 participants aged <30 or ≥75 years, to meet the recommended age range for heart age calculation; 74,834 participants with self-reported coronary heart disease, myocardial infarction, or stroke at baseline; 2,929 pregnant women; and 90,409 participants with missing covariates used for blood pressure prediction, leaving 578,525 participants for analysis.
For estimation of heart age, the sex-specific non-laboratorybased Framingham Risk Score (FRS) was used to estimate the risk for developing CVD in the next 10 years among BRFSS participants, which required the use of the following self-reported attributes: age, current smoking status, antihypertensive medication use, diabetes status, and body mass index (BMI) (10) . In addition, because the non-laboratorybased FRS requires the use of systolic blood pressure and BRFSS data do not include measured systolic blood pressure for participants, a previously published method to estimate participants' systolic blood pressure was used (12) . In brief, using National Health and Nutrition Examination Survey (NHANES) 2007-2012 data, four sex-and hypertensionstatus-specific multivariable linear regression models were developed to predict systolic blood pressure. These NHANESderived parameters were then applied to the comparable variables among BRFSS participants to predict each person's systolic blood pressure. After calculating participants' FRS using their predicted systolic blood pressure, their FRS result was translated to the corresponding predicted heart age, with the upper limit of predicted heart age set at 100 years (10) .
Age-standardized and weighted means and prevalence and 95% confidence intervals (CIs) were calculated for participants' chronological age, predicted heart age, the difference between predicted heart age and chronological age (defined as excess heart age). Prevalence of participants whose excess heart age was ≥5 years was calculated by age group (30-39, 40-49, 50-59, and 60-74 years), race/ethnicity (non-Hispanic white [white], non-Hispanic black [black], Hispanic, and others), education (<high school, high school, and >high school), annual household income (<$35,000 or ≥$35,000), and state. Multivariable linear regression models were used to estimate racial disparities in the difference of excess heart age among racial/ethnic groups by age, education, and household income group. Data were analyzed using statistical software that accounted for each surveys' complex sampling design.
Results
Among 236,101 men and 342,424 women, the mean weighted chronological ages were 47.8 and 47.9 years, respectively ( Table 1 ). The corresponding predicted heart ages and excess heart ages were 55.6 and 53.3 and 7.8 and 5.4 years for men and women, respectively (Table 1) . Among men, blacks had the highest predicted heart age (58.7 years) followed by Hispanics (55.7 years), whites (55.3 years) and others (54.7 years). Among women, the corresponding values by race/ethnicity were 58.9 years, 53.5 years, 52.5 years, and 52.3 years, respectively. Excess heart age increased with age and decreased as education and household income increased. Overall, approximately 69.1 million (43.7%) U.S. adults aged 30-74 years had excess heart age ≥5 years. † Prevalence of excess heart age ≥5 years was 48.8% among men and 38.5% among women; among both sexes, prevalence was higher among blacks compared with whites, increased with age, and decreased with greater education and household income (Table 1) .
Among men, the adjusted difference in excess heart age between blacks and whites was 2.7 years, -1.2 years between Hispanics and whites, and 3.8 years between blacks and Hispanics ( Table 2 ). The corresponding numbers for women were 5.3 years, -1.6 years, and 7.0 years, respectively. The racial differences in predicted excess heart age tended to increase † To determine the number of persons with heart age greater than chronological age, the sex-specific prevalence of adults aged 30-39, 40-49, 50-59, and 60-74 years free from CVD was determined using NHANES 2007-2012 data. Next, these prevalence estimates were applied to the NHANES 2011-2012 age-and sex-specific noninstitutionalized U.S. civilian population counts to determine the number of adults by age category free from CVD during that period. Finally, the BRFSS 2011 and 2013 derived age-and sex-specific heart age prevalence estimates were applied to these population estimates to determine the age-and sex-specific count estimates averaged across 2011 and 2013.
with greater age, education, and household income for blacks compared with whites, but decrease for Hispanics compared with whites (Table 2) . For blacks compared with Hispanics, predicted excess heart age tended to increase with greater age, but decrease with greater education and household income. At the state level, age-standardized excess heart age was lowest in Utah for men (5.8 years) and women (2.8 years) and was highest in Mississippi for men (10.1 years) and women (9.1 years) ( Table 3) . Similar patterns were observed in the distribution of prevalence of excess heart age ≥5 years by sex and state (Table 3) .
Conclusions and Comment
The predicted heart age among surveyed U.S. adults aged 30-74 years was substantially higher than their chronological age. On average, men and women had a predicted heart age 7.8 and 5.4 years older, respectively, than their chronological age, if the selected CVD risk factors were in an ideal range (not smoking, having normal systolic blood pressure (≤120 mmHg) and BMI <25, and not having diabetes). One in two men and two in five women had a predicted heart age ≥5 years older than their chronological age. This finding of high prevalence of excess heart age was consistent with the findings of other studies that have documented only a small proportion of U.S. adults meeting ideal cardiovascular health metrics (13, 14) .
Among younger adults, predicted excess heart age was higher among men compared with women. For example, among men aged 30-39 years, the average predicted heart age was 3.8 years older than their chronological age, compared with -0.3 years among similarly aged women. This disparity aligns with other findings showing that the mean chronological age of men who have suffered an initial heart attack is about 7 years younger than that of women (65.0 versus 71.8 years) (1) . This pattern of greater excess heart age among men was consistent across all the age groups until age 60-74 years, where women's excess heart age surpassed that of men's.
This analysis revealed substantial racial/ethnic disparities in the predicted heart age, with blacks having significantly higher predicted heart age compared with that of other groups. When adjusted for age, education and household income, the excess heart age among black men was 3 or 4 years more than white or Hispanic men, respectively, and among black women was 5 or 7 years more than white and Hispanic women, respectively. The higher predicted heart age among blacks might reflect persistent racial disparities in CVD risk factors, § especially elevated hypertension prevalence among blacks (3, 4) .
Predicted heart age differed substantially among states. Among the five states with the highest age-standardized predicted excess heart age for men (Mississippi, Louisiana, West Virginia, Alabama, and Kentucky), the excess heart age was ≥9.7 years, and ≥59.0% of men had excess heart age ≥5 years. Women living in the five states with the highest age-standardized predicted heart age (Mississippi, Louisiana, Alabama, Arkansas, and West Virginia) had an average excess heart age ≥8.0 years, with ≥48.9% of women having excess heart age ≥5 years.
The findings in this report are subject to at least six limitations. First, heart age was calculated using model-estimated systolic blood pressure instead of measured systolic blood pressure. However, use of mean predicted systolic blood pressure in BRFSS participants has been shown to produce a nearly identical 10-year FRS for developing CVD to that of NHANES participants with measured systolic blood pressure (12) . Second, the non-laboratory-based FRS that was used to estimate heart age might result in higher predicted heart age from that calculated using laboratory-based FRS estimates (12) . Different CVD prediction models, including models developed using data from other cohorts that account for racial/ethnic differences in the effects of risk factors on CVD risk or that incorporate additional CVD risk factors (e.g., physical inactivity), might provide different predicted risk for developing CVD (5, 10, 15) ; therefore, the predicted heart age presented in this report should be interpreted with caution. Third, self-reported BMI and diabetes diagnosis were used to estimate heart age among BRFSS participants. Underreporting of BMI is well-documented in BRFSS, and this might underestimate heart age for some participants (16) ; however, studies indicate that diabetes status by self-report and that based on actual diagnoses have been in substantial agreement in BRFSS and in survey data (17, 18) . Fourth, BRFSS does not collect self-reported heart failure or peripheral artery disease status, so participants with these conditions were not able to be excluded from these analyses. Fifth, within-state differences in excess heart age likely exist; however, such differences could not be assessed adequately in this study because of limited sample size at the county level. Finally, FRS uses a selected set of CVD risk factors to predict the development of CVD (10) . Lifestyle changes, such as reducing consumption of sodium, being physically active, and eating a healthy diet, Abbreviation: CI = confidence interval. * Adjusted for age (30-39, 40-49, 50-59, and 60-74 years), education (<high school, high school, and >high school), and annual household income (<$35,000, ≥$35,000, and unknown). † Adjusted for age (30-39, 40-49, 50-59, and 60-74 years), education (<high school, high school, and >high school), household income (<$35,000, ≥$35,000, and unknown), and included an interaction term of age-by-race/ethnicity to estimate racial difference in excess heart age by age group. § Adjusted for age (30-39, 40-49, 50-59, and 60-74 years), education (<high school, high school, and >high school), household income (<$35,000, ≥$35,000, and unknown), and included an interaction term of education-by-race/ethnicity to estimate racial difference in excess heart age by educational attainment group. ¶ Adjusted for age (30-39, 40-49, 50-59, and 60-74 years), education (<high school, high school, and >high school), household income (<$35,000, ≥$35,000, and unknown), and included an interaction term of household income-by-race/ethnicity to estimate racial difference in excess heart age by household income level. ** p-value based on t-tests across the age group.
† † p-value based on pairwise t-tests. also play an important role in reducing incidence of CVD but are not included in FRS heart age calculations (19) . Studies suggest that >75% of CVD could be prevented or postponed by controlling and managing specific CVD risk factors through lifestyle changes and/or adherence to recommended treatments (19) (20) (21) . One important component of the Million Hearts initiative (http://millionhearts.hhs.gov), a national effort to improve access to and quality of care to reduce the incidence of CVD through community and clinical prevention strategies, is to focus on the "ABCS" (aspirin when appropriate, blood pressure control, cholesterol management, and smoking cessation). Greater achievement of the ABCS, in addition to control of other CVD risk factors and reductions in racial and geographic CVD disparities, are critical for meeting the initiative's goal of preventing 1 million heart attacks, strokes, and other CVD-related events in 5 years.
Although traditional absolute CVD risk (e.g., 10-year CVD risk score) should continue to be used by clinicians to inform treatment and management, heart age might be an effective way to communicate individual-level risk for developing CVD and spur action to improve health. One study comparing the effect of using absolute CVD risk versus heart age on participants' risk perceptions and intention to make lifestyle changes suggested that heart age messaging led to significantly higher perceived risk and was more emotionally impactful for participants at higher actual CVD risk levels (7) . A randomized intervention trial concluded that communicating CVD risk using heart age versus absolute risk resulted in a greater reduction (-1.5 versus -0.3 year decrease in heart age) in CVD risk over the 1-year intervention period (22) . Adopting a healthy lifestyle could have a profound effect on reducing excess heart age. For example, a male smoker aged 50 years with untreated systolic blood pressure of 140 mm Hg, no diabetes, and a BMI of 30, has a predicted heart age of 72 years (74 years for a female with similar characteristics) (Figure) . ¶ Quitting smoking for 1 year alone would have reduced predicted heart age by 14 years (15 years), reducing systolic blood pressure to 120 mm Hg alone would have reduced predicted heart age by 6 years (10 years), and removing both risk factors would have lowered predicted heart age by 19 years (23 years). At the population-level, the use of predicted heart age might be an effective way to communicate CVD risk, to identify geographic regions and populations most in need of CVD risk factor improvement,** and to stimulate action at the state, county, or community level.
Considerable burden of elevated heart age exists in the United States, and statistically significant racial, sociodemographic, and regional disparities in heart age exist among U.S. adults aged 30-74 years. Use of heart age might simplify risk communication and motivate more persons, especially younger persons, to adopt healthier lifestyles and better comply with recommended therapeutic interventions to prevent heart disease and stroke. Moreover, its use might support public health efforts in geographic areas most at risk for poor CVD outcomes and support the implementation of programs and policies that increase the availability of heart-healthy lifestyle options within communities. ¶ A heart age calculator is available at http://www.cdc.gov/heartdisease/heartage.
htm. ** Supplementary Table 3 (available at http://stacks.cdc.gov/view/cdc/33002) demonstrates the effect of CVD risk factors included in non-laboratory-based FRS heart age calculations on population mean excess heart age estimates stratified by sex and chronological age.
Key Points
• Cardiovascular disease (heart disease and stroke) is the leading cause of death in the United States.
• People can determine their risk for having a heart attack or stroke during the next 10 years by calculating their 10-year risk score.
• An alternative, simpler way to look at their risk for heart attack and stroke is for people to calculate their heart age. Heart age is the predicted age of their heart and blood vessels based on their blood pressure, weight, and smoking and diabetes status. Comparing heart age with their chronological (actual) age can tell a person what their risk is for heart attack and stroke. The closer their heart age is to their actual age the lower their risk.
• This is the first national study to determine heart age for U.S. adults aged 30-74 years. Using information from the Framingham Heart Study and data collected from every U.S. state, the study estimates that, on average, U.S. men have a heart that is about 8 years older, and U.S. women 5 years older, than their actual age.
• About 69 million (43.7%) U.S. adults had a heart age 5 or more years older than their actual age. The average difference between heart age and actual age was lowest in Utah for men and women (5.8 and 2.8 years, respectively) and highest in Mississippi (10.1 and 9.1 years, respectively), and higher among nonHispanic blacks compared to other race/ethnic groups. • More than 3 in 4 heart attacks and strokes could be avoided or postponed if people manage or control their cardiovascular risk factors. • Doctors and their patients can calculate heart age and discuss a plan to reduce their risks for heart attack and stroke based on heart age (http://www.cdc.gov/ heartdisease/heartage.htm).
• Additional information is available at http://www.cdc. gov/vitalsigns.
Recommendations Regarding Interventions to Increase Appropriate Vaccination -Community Preventive Services Task Force
The Community Preventive Services Task Force posted new information about two recommendations to increase appropriate vaccination on its website: 1) "Community-Based Interventions Implemented in Combination," available at http://www. thecommunityguide.org/vaccines/communityinterventions.html, and 2) "Health Care System-Based Interventions Implemented in Combination," available at http://www.thecommunityguide. org/vaccines/healthsysteminterventions.html.
Established in 1996 by the U.S. Department of Health and Human Services, the task force is an independent, nonfederal, uncompensated panel of public health and prevention experts whose members are appointed by the Director of CDC. The task force provides information for a wide range of decision makers on programs, services, and policies aimed at improving population health. Although CDC provides administrative, research, and technical support for the task force, the recommendations developed are those of the task force and do not undergo review or approval by CDC.
Errata

Vol. 64, No. 34
In the report, "Vital Signs: Predicted Heart Age and Racial Disparities in Heart Age Among U.S. Adults at the State Level," on pages 956-7, the Figure had multiple errors. The corrected Figure follows. 
